StockWatch
·

Tempsens Instruments (India) Ltd Q2 FY27 Results

TEMPSENSQ2 FY27 Results
Filing
TEMPSENS · Q2 FY27 · THE VERDICT

34% Growth Masks 410 bps Margin Squeeze

Tempsens delivered strong revenue growth, but EBITDA margin compressed sharply due to consolidated entities and cost inflation. The real question: does management absorb these costs in H2, or is the margin miss structural?

13 Nov 2026 · 6 min read
Reported PAT

₹35.7 Cr

+18.1% YoY

EBITDA

₹54.9 Cr

+11.9% YoY

EBITDA margin

21.2%

−410 bps from 25.2%

Revenue

₹255 Cr

+33.7% YoY

Tempsens posted a headline quarter: 34% revenue growth, 79% export surge, and PAT up 18%. On the surface, a solid print. But the earnings tell a different story. EBITDA margin collapsed 410 basis points to 21.2% from 25.2%, dragging profit growth to half the revenue growth rate. The culprits are structural — consolidated acquisition entities with lower margins, an ESOP charge of ₹1.1 Cr, and employee costs up 41% — and management's timeline for absorption remains vague.

The gap: where the margin went

Management cites three headwinds. First, Tempsens Germany and Tempsens Polska (consolidated in FY27, not FY26) carry lower gross margins than the India standalone business. Second, the prior-year H1 benefited from a one-time high-margin defense order that didn't repeat. Third, employee costs spiked 41% to ₹42.1 Cr for capacity hiring. The company claims these will be absorbed as new product lines ramp and utilization improves, but on the call offered no specific margin target or timeline — only that profitability will 'improve progressively' in H2.

H1 EBITDA Margin
09.4118.8228.2225.2FY26 full-year21.2Q2 FY27 H1
410 basis point compression. Drivers: consolidated entities, ESOP charges (₹1.1 Cr), employee cost inflation (+41%).
Management claims vs. what holds up

Export revenue more than doubled

Supported

₹94 Cr vs ₹47 Cr prior year (37% vs 25% of revenue)

EBITDA grew 12%

Supported

₹54.9 Cr vs ₹49.1 Cr = 11.9%

Gross margin 45.7%, in line with FY26 46%

Overstated

45.7% reported, but prior year included one-time defense order; new consolidated entities lower-margin

Employee cost spike will be absorbed by revenue growth

Contradicted

Employee costs +41% to ₹42.1 Cr; absorption depends on H2 execution, not yet proven

What changed on this call

Three structural shifts emerged:

  • Export mix shift: Exports now ₹94 Cr (37% of product revenue) vs ₹47 Cr (25%) prior year; +79% YoY driven by Tempsens Germany & Polska organic growth plus new Ajman office for Gulf region

  • OEM business emergence: Fuel cell OEM orders confirmed with ~1 year visibility; life science furnace approvals (ETL, CE) beginning ramping Oct 2026; mid-voltage heater prototype stage. Target ~15% of revenue 'in the next year'

  • Balance sheet debt reduction: ₹55 Cr repaid from IPO proceeds (Aug 2026); net debt ₹40.7 Cr vs ₹77.9 Cr prior; debt-to-equity 0.06x from 0.15x

The bull-bear ledger

Bull case
  • Strong organic revenue growth (~25% ex-consolidation boost)

  • Export momentum doubled; now 37% of revenue with 1–2 year OEM visibility vs 3–4 months traditional

  • ₹500 Cr aggregate peak revenue potential from 5 capacity projects (Q4 FY27–Q3 FY28)

  • Post-IPO balance sheet strength; debt halved; ample cash (OCF ₹50.7 Cr +16.2%)

  • Niche, defensible products (customized sensors, furnaces, cables); moat from long qualification cycles

Bear case
  • EBITDA margin compressed 410 bps (21.2% from 25.2%); recovery timeline vague

  • Employee cost +41% to ₹42.1 Cr; absorption claim unproven and execution-dependent

  • PAT growth +18% lags revenue +34%; signals earnings quality deterioration, not momentum

  • OEM revenue target (15% FY28) early-stage; supplies just ramping; timing uncertain

  • 5 concurrent capex projects at risk of cost overrun or timeline slip (12-month window)

  • Consolidated entities (Germany, Poland) structurally lower-margin; uplift path unclear

Risks, ranked by how much they should concern a holder

Margin recovery execution

High

EBITDA margin fell 410 bps to 21.2%; management vague on H2 recovery (no specific target or timeline). If cost absorption fails, FY27 margin miss could be structural and repeat into FY28.

Capacity expansion execution

High

5 concurrent projects (Q4 FY27–Q3 FY28) targeting ₹500 Cr peak revenue potential. Execution/cost overrun risk high; timeline slip delays profitability uplift.

OEM business materialization

High

15% revenue target for FY28 stated vaguely; supplies ramping but bookings/revenue timing unquantified. If OEM ramp slower than guided, margin recovery delayed and full-year growth misses.

Consolidated entity dilution

Medium

Germany & Polska lower-margin acquisitions pulling blended margin down 410 bps; integration costs unquantified; uplift path unclear. Risk of structural margin overhang if not resolved.

Forex exposure

Low

Exports 37% of revenue; ops in Germany, Poland, UAE, Mexico. Currency fluctuation or geopolitical disruption manageable at current rates; hedging strategy not disclosed.

How the street is positioned

The stock is down 12.5% from its all-time high of ₹614.85, currently trading at ₹537.8 — just below its 50-day average (₹539.32) and comfortably above its 20-day (₹520.51). The 52-week range of ₹470.6–₹614.85 places it in the upper half, but the post-IPO pop has faded. RSI at 51.8 (neutral) and volume trending downward suggest cautious positioning. Bulk deal activity over the last 6 months shows balanced buy-sell flows from entities like QE Securities and JunoMoneta, with no insider or promoter-linked red flags near the highs. The market is not panicking — but it's also not rushing back in. The modest drawdown and reduced volume are consistent with a market waiting for margin recovery proof in H2 results, not a fundamental repricing.

The debate

What to watch next
  • 1 · H2 FY27 EBITDA margin trajectory

    Does margin recover toward 24–25%, or stay at 21%? This resolves whether cost inflation is temporary or structural. Watch for employee cost stabilization and new product gross margins.

  • 2 · OEM revenue realization in H2 & Q3 FY27

    How much fuel cell, furnace, and heater revenue flows in H2? Early ramps matter less than confirmed orders and revenue visibility for FY28. If OEM supply lags guidance, the 15% target for FY28 is at risk.

  • 3 · Q4 FY27 capacity project commissioning

    Do the first capex projects (Unit 8 cable plant, furnace expansion) come online on budget and on time? Schedule slip or cost overrun signals execution headwinds across the pipeline.

Tempsens delivered a headline quarter, but the earnings quality is mixed. Strong growth (+34%) is real, but it's being diluted by margin compression (410 bps) from consolidated entities and cost inflation. Management's vagueness on near-term absorption is the red flag.

The stock's 12.5% pullback from its all-time high is rational — the market is waiting for proof that H2 margins recover and the capacity pipeline executes. This is not a panic sell or a screaming buy. It's a stock that needs to demonstrate disciplined cost management and on-time project delivery.

The number to track from here is Q2 FY27 H1 EBITDA margin guidance and realized trajectory in H2 onwards. If margin stabilizes in the 23–25% range and OEM ramps confirm, the stock has room to recover. If margin stays at 21% or compresses further, more downside is likely. Until then, the story is execution-dependent, not a conviction buy.

Informational and educational content only. Not investment advice.